Back to Search
Start Over
Clozapine placental passage at delivery: an update
- Source :
- European Psychiatry, Vol 65, Pp S235-S236 (2022)
- Publication Year :
- 2022
- Publisher :
- Cambridge University Press, 2022.
-
Abstract
- Introduction Clozapine is an effective second-generation antipsychotic that is approved for treatment-resistant schizophrenia and risk reduction of recurrent suicidal behavior in schizophrenia or schizoaffective disorder. Its available pregnancy pharmacikinetics data remain limited, which presents a challenge for clinicians managing women taking clozapine during perinatal period . Objectives The aim of this study was to provide new data of clozapine and norclozapine placental passage and neonatal outcomes. Methods We retrospectively studied a consecutive case series of six pregnancies where there was clozapine exposure (5 in politherapy and 1 in monotherapy). Clozapine and norclozapine serum concentrations were determined in the mother-infant pairs on the day of delivery (intrapartum maternal blood and umbilical cord blood respectively) and measured using a validated high-performance liquid chromatography method. The within- and between-day precision expressed as the coefficient of variation (CV)% were both
- Subjects :
- Delivery
Mother-infant pair
Placental passage
clozapine
Psychiatry
RC435-571
Subjects
Details
- Language :
- English
- ISSN :
- 09249338 and 17783585
- Volume :
- 65
- Database :
- Directory of Open Access Journals
- Journal :
- European Psychiatry
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.699581f493564ed1aa524a5e3a0f845f
- Document Type :
- article
- Full Text :
- https://doi.org/10.1192/j.eurpsy.2022.610